Immune reset: CAR-T therapy takes on lupus
NCT ID NCT06310811
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-stage trial tests a new treatment called RD06-04, a CAR-T cell therapy, in 12 people with moderate to severe lupus. The therapy aims to target and reset immune cells that attack the body. The main goal is to check safety and find the right dose, with a close watch for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
RD06-04 cells (a type of CAR-T cell therapy that targets CD19 on immune cells)
What this could lead to
If it works, this could point toward a new way to control lupus by resetting the immune system, potentially reducing the need for lifelong medication.
What could go wrong
This is a very early, small Phase I trial with only 12 participants. It is currently suspended, and the main goal is safety, not proof of effectiveness. CAR-T therapy can cause serious side effects like cytokine release syndrome.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SAFETY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Wuhan Union
Wuhan, Hubei, 430000, China